Cargando…

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study

OBJECTIVE: When initiating a new therapy in patients with rheumatoid arthritis (RA), current treatment recommendations suggest escalating therapy in case of poor clinical improvement by 3 months or if the treatment target has not been reached by 6 months. We investigated which disease activity impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Norvang, Vibeke, Sexton, Joseph, Kristianslund, Eirik K, Olsen, Inge C, Uhlig, Till, Bakland, Gunnstein, Krøll, Frode, Rødevand, Erik, Wierød, Ada, Kvien, Tore K, Smolen, Josef S, Aletaha, Daniel, Haavardsholm, Espen A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242030/
https://www.ncbi.nlm.nih.gov/pubmed/30488000
http://dx.doi.org/10.1136/rmdopen-2018-000773
_version_ 1783371809694941184
author Norvang, Vibeke
Sexton, Joseph
Kristianslund, Eirik K
Olsen, Inge C
Uhlig, Till
Bakland, Gunnstein
Krøll, Frode
Rødevand, Erik
Wierød, Ada
Kvien, Tore K
Smolen, Josef S
Aletaha, Daniel
Haavardsholm, Espen A
author_facet Norvang, Vibeke
Sexton, Joseph
Kristianslund, Eirik K
Olsen, Inge C
Uhlig, Till
Bakland, Gunnstein
Krøll, Frode
Rødevand, Erik
Wierød, Ada
Kvien, Tore K
Smolen, Josef S
Aletaha, Daniel
Haavardsholm, Espen A
author_sort Norvang, Vibeke
collection PubMed
description OBJECTIVE: When initiating a new therapy in patients with rheumatoid arthritis (RA), current treatment recommendations suggest escalating therapy in case of poor clinical improvement by 3 months or if the treatment target has not been reached by 6 months. We investigated which disease activity improvement levels at 3 months predicted achievement of the treatment targets at 6 months in a real-life clinical setting. METHODS: We included 1610 patients with RA enrolled in the NOR-DMARD study between 2000 and 2012. Analyses were performed for the total group of patients and repeated for subgroups stratified by baseline disease activity, disease duration or treatment with methotrexate or a tumour necrosis factor inhibitor. We used a diagnostic test approach to explore the associations between 3-month response and 6-month outcome. RESULTS: Not achieving 50% improvement in Simplified Disease Activity Index (SDAI) by 3 months significantly decreased the likelihood of reaching remission at 6 months in all subgroups (negative likelihood ratios (LRs−) 0.15–0.36). Patients with high disease activity when initiating treatment were likely to fail reaching remission if they achieved less than SDAI 70% response by 3 months (LR− 0.25 and negative predictive value 0.98). Achieving a major response (SDAI 85%) at 3 months significantly increased the likelihood of reaching remission at 6 months (LRs+ 6.56). CONCLUSION: Levels of 3-month disease activity improvement can inform clinicians when deciding to continue or adjust ongoing therapy in a treat-to-target strategy aiming for remission or low disease activity within 6 months. The required levels of 3-month improvement varied with baseline disease activity.
format Online
Article
Text
id pubmed-6242030
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-62420302018-11-28 Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study Norvang, Vibeke Sexton, Joseph Kristianslund, Eirik K Olsen, Inge C Uhlig, Till Bakland, Gunnstein Krøll, Frode Rødevand, Erik Wierød, Ada Kvien, Tore K Smolen, Josef S Aletaha, Daniel Haavardsholm, Espen A RMD Open Rheumatoid Arthritis OBJECTIVE: When initiating a new therapy in patients with rheumatoid arthritis (RA), current treatment recommendations suggest escalating therapy in case of poor clinical improvement by 3 months or if the treatment target has not been reached by 6 months. We investigated which disease activity improvement levels at 3 months predicted achievement of the treatment targets at 6 months in a real-life clinical setting. METHODS: We included 1610 patients with RA enrolled in the NOR-DMARD study between 2000 and 2012. Analyses were performed for the total group of patients and repeated for subgroups stratified by baseline disease activity, disease duration or treatment with methotrexate or a tumour necrosis factor inhibitor. We used a diagnostic test approach to explore the associations between 3-month response and 6-month outcome. RESULTS: Not achieving 50% improvement in Simplified Disease Activity Index (SDAI) by 3 months significantly decreased the likelihood of reaching remission at 6 months in all subgroups (negative likelihood ratios (LRs−) 0.15–0.36). Patients with high disease activity when initiating treatment were likely to fail reaching remission if they achieved less than SDAI 70% response by 3 months (LR− 0.25 and negative predictive value 0.98). Achieving a major response (SDAI 85%) at 3 months significantly increased the likelihood of reaching remission at 6 months (LRs+ 6.56). CONCLUSION: Levels of 3-month disease activity improvement can inform clinicians when deciding to continue or adjust ongoing therapy in a treat-to-target strategy aiming for remission or low disease activity within 6 months. The required levels of 3-month improvement varied with baseline disease activity. BMJ Publishing Group 2018-10-26 /pmc/articles/PMC6242030/ /pubmed/30488000 http://dx.doi.org/10.1136/rmdopen-2018-000773 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Rheumatoid Arthritis
Norvang, Vibeke
Sexton, Joseph
Kristianslund, Eirik K
Olsen, Inge C
Uhlig, Till
Bakland, Gunnstein
Krøll, Frode
Rødevand, Erik
Wierød, Ada
Kvien, Tore K
Smolen, Josef S
Aletaha, Daniel
Haavardsholm, Espen A
Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
title Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
title_full Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
title_fullStr Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
title_full_unstemmed Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
title_short Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
title_sort predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the nor-dmard study
topic Rheumatoid Arthritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242030/
https://www.ncbi.nlm.nih.gov/pubmed/30488000
http://dx.doi.org/10.1136/rmdopen-2018-000773
work_keys_str_mv AT norvangvibeke predictingachievementofthetreatmenttargetsat6monthsfrom3monthresponselevelsinrheumatoidarthritisdatafromreallifefollowupinthenordmardstudy
AT sextonjoseph predictingachievementofthetreatmenttargetsat6monthsfrom3monthresponselevelsinrheumatoidarthritisdatafromreallifefollowupinthenordmardstudy
AT kristianslundeirikk predictingachievementofthetreatmenttargetsat6monthsfrom3monthresponselevelsinrheumatoidarthritisdatafromreallifefollowupinthenordmardstudy
AT olseningec predictingachievementofthetreatmenttargetsat6monthsfrom3monthresponselevelsinrheumatoidarthritisdatafromreallifefollowupinthenordmardstudy
AT uhligtill predictingachievementofthetreatmenttargetsat6monthsfrom3monthresponselevelsinrheumatoidarthritisdatafromreallifefollowupinthenordmardstudy
AT baklandgunnstein predictingachievementofthetreatmenttargetsat6monthsfrom3monthresponselevelsinrheumatoidarthritisdatafromreallifefollowupinthenordmardstudy
AT krøllfrode predictingachievementofthetreatmenttargetsat6monthsfrom3monthresponselevelsinrheumatoidarthritisdatafromreallifefollowupinthenordmardstudy
AT rødevanderik predictingachievementofthetreatmenttargetsat6monthsfrom3monthresponselevelsinrheumatoidarthritisdatafromreallifefollowupinthenordmardstudy
AT wierødada predictingachievementofthetreatmenttargetsat6monthsfrom3monthresponselevelsinrheumatoidarthritisdatafromreallifefollowupinthenordmardstudy
AT kvientorek predictingachievementofthetreatmenttargetsat6monthsfrom3monthresponselevelsinrheumatoidarthritisdatafromreallifefollowupinthenordmardstudy
AT smolenjosefs predictingachievementofthetreatmenttargetsat6monthsfrom3monthresponselevelsinrheumatoidarthritisdatafromreallifefollowupinthenordmardstudy
AT aletahadaniel predictingachievementofthetreatmenttargetsat6monthsfrom3monthresponselevelsinrheumatoidarthritisdatafromreallifefollowupinthenordmardstudy
AT haavardsholmespena predictingachievementofthetreatmenttargetsat6monthsfrom3monthresponselevelsinrheumatoidarthritisdatafromreallifefollowupinthenordmardstudy